Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36499 | 0.88 | TSHR (0.67) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL12035154 | 0.88 | SMN1; SMN2 (0.55) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL23251208 | 0.86 | TSHR (0.55) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL12280535 | 0.86 | TSHR (0.55) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL20779827 | 0.86 | TSHR (0.55) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL20094 | 0.85 | TSHR (0.79) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL22418810 | 0.85 | TSHR (0.79) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL17197994 | 0.85 | TSHR (0.79) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL16684221 | 0.85 | TSHR (0.79) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL5319100 | 0.84 | TSHR (0.57) | TSHRMAPK1SMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12044648-B2 | Analyte sensors and sensing methods featuring low-potential detection | ABBOTT DIABETES CARE INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11802229-B2 | Low-modulus high-adhesion silane-modified polyether sealant for prefabricated building, and preparation method therefor | GUANGZHOU BAIYUN CHEMICAL INDUSTRY CO., LTD. (CN) | 2023-10-31 | — | — | US | disclosed |
| US-20140039062-A1 | INJECTABLE DEVICE AND METHOD FOR SCULPTING, AUGMENTING OR CORRECTING FACIAL FEATURES SUCH AS THE CHIN | ALLERGAN, INC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20120071437-A1 | TUNABLE CROSSLINKED POLYSACCHARIDE COMPOSITIONS | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110077737-A1 | Tunably Crosslinked Polysaccharide Compositions | ALLERGAN, INC. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071437-A1 | TUNABLE CROSSLINKED POLYSACCHARIDE COMPOSITIONS | CD44, COL2A1, FN1 | TSHR 1758/4885MAPK1 4308/4885SMN1; SMN2 3197/4885 |
| US-20110077737-A1 | Tunably Crosslinked Polysaccharide Compositions | ALG1, CD44, COL2A1 | TSHR 2255/4885MAPK1 4371/4885SMN1; SMN2 1909/4885 |
| US-20140039062-A1 | INJECTABLE DEVICE AND METHOD FOR SCULPTING, AUGMENTING OR CORRECTING FACIAL FEATURES SUCH AS THE CHIN | FN1, FGF1, HPSE | TSHR 850/4885MAPK1 4300/4885SMN1; SMN2 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.